1.The overall progress and challenges of Shanghai health care for the last 30 years since reform and opening up
Tiehui WENG ; Lingfang WU ; Xuefeng LIU ; Jun LIU ; Mingzhong YE ; Shuqiong WANG ; Zeping XIAO ; Weijun HAN ; Jianguang XU ; Longxing WANG ; Guangwen GAO ; Chunyan XIE
Chinese Journal of Hospital Administration 2011;27(7):490-493
Marked by the Third Plenary Session of the Eleventh Central Committee of the CPC, Shanghai health care started a journey of reform and opening up as with other sectors. This essay reviews various stages Shanghai health care experienced and the achievements for the last 30 years since reform and opening up, and analyzes the challenges Shanghai health care faces currently. On this basis, the essay summaries the experiences and lessons learned from Shanghai health care reform and development.
2.Basic framework and thought of deepening reform of Shanghai healthcare system
Jianguang XU ; Chen FU ; Wenjuan ZHU ; Xuefeng LIU ; Yumei PENG ; Xianji WANG ; Mingzhong YE ; Zeping XIAO ; Longxing WANG ; Jin MA ; Wenhua TIAN ; Wen CHEN
Chinese Journal of Hospital Administration 2011;27(7):483-485
Under the general requirements of China's national health reform, the basic framework of Shanghai's health reform was constructed at five different aspects the long term vision, goal, strategies, measures, supportive reform activities. The general thought of Shanghai's health reform can be concluded into two aspects: first, establishing a basic healthcare system of covering both urban and rural residents universally; second, enhancing the foundation of enabling sustainable health development.
3.CD20 +T cells in multiple sclerosis
Chinese Journal of Neurology 2024;57(1):92-97
CD20 is a classic marker expressed by B cells. However, recent studies have found that CD20 is also dimly expressed on a small subset of CD3 +T cells, and the CD20 +T cells play an important proinflammatory role in multiple sclerosis (MS). Anti-CD20 monoclonal antibodies selectively deplete CD20 +T cells and effectively suppress inflammatory disease activity. Although CD20 +T cells have received increasing attention, the understanding of these cells is currently still in its infancy. This article provides an overview of the current knowledge about advanced progress of CD20 +T cells as well as their roles in MS.
4.Effect of high-intensity focused ultrasound combined with gemcitabine on subcutaneous pancreatic cancer in nude mice.
Ying MAO ; Liaoqiong FANG ; Longxing LIU ; Haixia HU ; Faqi LI ; Hui ZHU
Journal of Southern Medical University 2013;33(12):1713-1717
OBJECTIVETo investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer.
METHODSNude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry.
RESULTSThe tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group.
CONCLUSIONHIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.
Animals ; Cell Line, Tumor ; Combined Modality Therapy ; Deoxycytidine ; analogs & derivatives ; therapeutic use ; High-Intensity Focused Ultrasound Ablation ; Humans ; Immunohistochemistry ; Mice ; Mice, Nude ; Pancreatic Neoplasms ; therapy ; Transplantation, Heterologous ; Vascular Endothelial Growth Factor A ; metabolism
5.Effect of high-intensity focused ultrasound combined with gemcitabine on subcutaneous pancreatic cancer in nude mice
Ying MAO ; Liaoqiong FANG ; Longxing LIU ; Haixia HU ; Faqi LI ; Hui ZHU
Journal of Southern Medical University 2013;(12):1713-1717
Objective To investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer. Methods Nude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry. Results The tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group. Conclusion HIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.
6.Effect of high-intensity focused ultrasound combined with gemcitabine on subcutaneous pancreatic cancer in nude mice
Ying MAO ; Liaoqiong FANG ; Longxing LIU ; Haixia HU ; Faqi LI ; Hui ZHU
Journal of Southern Medical University 2013;(12):1713-1717
Objective To investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer. Methods Nude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry. Results The tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group. Conclusion HIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.
7.Difference analysis of chemical components in roots and rhizomes of 3 medicinal plants of Gentiana from the same origin
Rui LI ; Yingying ZHANG ; Weihong LIU ; Yanqiu SONG ; Longxing LI ; Haifeng LI
China Pharmacy 2023;34(3):303-308
OBJECTIVE To provide reference for exploring alternative resources of Gentiana rigescens from the plants of Gentiana. METHODS The contents of four components (gentiopicroside, swertiamarin, swertioside and amarogentin) in the roots and rhizomes from 3 plants of Gentiana (G. rigescens, G. cephalantha, G. delavayi) were determined by high-performance liquid chromatography (HPLC). The chemical compositions in the above roots and rhizomes were identified by ultra-performance liquid chromatography electrospray ionization quarter-time of flight mass spectrometry (UPLC-ESI-Q-TOF-MS), and the differences were analyzed by principal component analysis (PCA). RESULTS Four active components such as gentiopicroside, swertiamarin, swertioside and amarogentin were detected in the roots and rhizomes of G. rigescens and G. cephalantha, and the contents of the four components were similar in both. The contents of gentiopicroside in the root and rhizome of G. cephalantha and G.rigescens were more than four times of the limit standard of the Chinese Pharmacopoeia (Part Ⅰ) in 2020; However, only swertiamarin, swertioside and amarogentin were detected in the roots and rhizomes of G.delavayi, and the contents of swertioside and amarogentin were 34.12 and 8.81 times of those of G. rigescens, respectively. In addition, a total of 33 compounds 术。E-mail:515227235@qq.com were identified from the roots and rhizomes of 3 plants of Gentiana by UPLC-ESI-Q-TOF-MS, mainly iridoids. Additionally, G. rigescens and G. cephalantha contained xantones, G. delavayi contained flavonoids. PCA showed that there was a small difference between G. rigescens and G. cephalantha; however, there was a big difference between G. delavayi and G. rigescens. CONCLUSIONS The difference between the roots and rhizomes of G. cephalantha and G. rigescens from the same origin is small and there is substitutability; while the difference in the chemical components from roots and rhizomes between G. delavayi and G. rigescens is great and G. delavayi cannot be used as medicine instead of G. rigescens.